Novartis AG NVSEF OTC

Novartis AG (NVSEF) generated $2.15B in operating cash flow for quarter ending 2025-12-31. After capital expenditures of $625.58M, free cash flow was $1.52B.

Free cash flow margin was 11.3% of revenue. Cash conversion ratio was 0.88x, suggesting some earnings are non-cash.

The company returned $1.45B in share buybacks to shareholders during the quarter.

Criteria supported by this page:

• HEALTH (67/100, Partial) — cash generation is adequate but may not fully cover debt in stressed conditions
• MOAT (94/100, Pass) — $1.52B (11.3% margin) supports a durable competitive advantage
• INCOME (85/100) — Cash conversion ratio was 0.88x suggests some earnings are non-cash items

Overall SharesGrow Score: 73/100 with 5/7 criteria passed.